Trials / Completed
CompletedNCT00333567
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy of a Single Dose of Lumiracoxib 400 mg Given Pre-Emptively Versus Post-Operatively, in Reducing Pain Associated With Ambulatory Arthroscopic Knee Surgery
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic knee surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lumiracoxib |
Timeline
- Start date
- 2006-08-01
- First posted
- 2006-06-05
- Last updated
- 2007-12-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00333567. Inclusion in this directory is not an endorsement.